Immune cell research for chronic hepatitis B
Part of Digestive system, Infections clinical trials.
This study looks at how a specific protein (ANKRD11) affects immune cells in people with chronic hepatitis B. By understanding this, researchers hope to find ways to help your immune system fight the virus better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 65 years old
- You have had hepatitis B for at least 6 months (HBsAg positive)
- You have a specific immune marker called HLA-A11 (a blood test will confirm)
- You are not infected with HIV, hepatitis C, or syphilis
- You do not have liver cancer, severe liver damage, or other serious organ diseases
- You have not recently taken immune-suppressing drugs or had cell therapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects a small sample of liver cells to understand how hepatitis B virus behaves in the liver and how the immune system responds. This could help improve future treatments for chronic hepatitis B.
This trial tests a new injection called AHB-137 for people with chronic hepatitis B. It aims to see if the drug is safe and helps control the virus.
This study tests a new combination of antiviral medicine and an immune-boosting therapy for adults with chronic hepatitis B. It is designed for people who are in the active phase of the infection and have not been treated before.
This trial is for people with chronic hepatitis B who have already cleared the virus with interferon treatment. It tests ongoing strategies to help maintain their health and prevent the virus from coming back.
This study tests a new injection called AHB-137 in people with chronic hepatitis B who have never received antiviral treatment. The goal is to see if it can help reduce the hepatitis B virus in the body and improve liver health.
This study tests how a new investigational drug called AHB-137 moves through your body and affects safety in people with mild-to-moderate liver problems compared to people with normal liver function. The goal is to understand if the drug works safely in people whose livers don't work as well as they should.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.